---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-083866"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:50:22.474452+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics appoints Baker Tilly as auditor after Moss Adams merger

## Summary
- Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
- Audit Committee approved Baker Tilly as successor for fiscal year ending Dec 31, 2025.
- No disagreements or reportable events occurred during the past two fiscal years or interim period.
- Moss Adams' 2024 audit report was unqualified and contained no adverse opinion.

## SEC filing metadata
- accession: 0000950170-25-083866
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/0000950170-25-083866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/lctx-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-083866
- JSON: https://secwatch.observer/filing/0000950170-25-083866.json
- Plain text: https://secwatch.observer/filing/0000950170-25-083866.txt

## Key facts
- Auditor Changes
  Lineage Cell Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
  - Action: engagement
  - Auditor: Baker Tilly US, LLP
  source text: the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/0000950170-25-083866-index.htm
- Auditor Changes
  Moss Adams LLP resigned as auditor of Lineage Cell Therapeutics, Inc..
  - Action: resignation
  - Auditor: Moss Adams LLP
  - Successor: Baker Tilly US, LLP
  source text: In connection with the notification of the merger, Moss Adams resigned as the auditors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/0000950170-25-083866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.